LillyDirect launches in the United Kingdom

Eli Lilly has launched a UK version of LillyDirect, the direct-to-patient sales channel that has become central to how Americans buy Mounjaro and Zepbound (tirzepatide) ^[1]. The UK service started June 25, 2026, and its first product is Mounjaro, the tirzepatide brand approved there for weight loss and type 2 diabetes ^[1].

The UK model works differently than in the US because British law bars drugmakers from shipping prescription medicines directly to patients ^[1]. Instead, LillyDirect UK is a post-prescription dispensing and delivery service. A patient must first get a private prescription from a UK-regulated healthcare provider registered with the platform. That prescription is then filled and delivered by one of Lilly's dispensing partners, currently Blueco Healthcare's Onescript service and Pharmacy2U, with the medicine shipped in discreet packaging and tracked in real time ^[1]. Lilly says it "plays no role in any clinical decisions relating to patient care" ^[1].

A major driver behind the launch is counterfeit risk. Because Mounjaro is hard to get through Britain's National Health Service due to eligibility restrictions, many UK patients already rely on private prescriptions, which Lilly says has exposed some of them to falsified copies of the drug that may contain no active ingredient or, in some reported international cases, other hazardous substances such as insulin ^[1]. Lilly says the new channel is meant to guarantee that "authentic, Lilly-manufactured medicines are delivered to patients," reducing the chance that counterfeit products reach people who order online ^[1].

Lilly has signaled the UK platform could expand beyond Mounjaro. The company said it may eventually add Foundayo (orforglipron), its oral GLP-1 pill, which was under review by the UK's medicines regulator, the MHRA, as of the announcement and could become available for private prescription before the end of 2026 if approved ^[1]. Khalil Asmar, Lilly's vice president of cardiometabolic health for the UK and Northern Europe, tied the launch to the company's 150th anniversary, saying the goal is to make sure that once a patient is prescribed a Lilly medicine, "receiving it is as simple, secure, and straightforward as possible" ^[1].

Why it matters for patients

This launch is a UK development, not a US one, so it does not change how Americans order Mounjaro, Zepbound, or any semaglutide product through the existing US version of LillyDirect ^[1]. But it shows Lilly extending the same brand and delivery infrastructure it built for US direct-to-patient sales into a second major market, which suggests the company sees this model as a long-term part of how it distributes GLP-1 drugs ^[1].

The counterfeit concern raised in the UK is also relevant context for US readers. Falsified versions of tirzepatide and semaglutide products have circulated internationally, sometimes containing no active ingredient or other substances such as insulin ^[1]. Lilly's stated rationale for LillyDirect, in both markets, is to create a traceable supply chain from manufacturer to patient that reduces exposure to unauthorized or fake products ^[1].

The UK case also illustrates that different countries handle direct-to-patient pharma sales differently based on their own laws. Where the US LillyDirect model can involve more direct manufacturer-to-patient logistics, UK law requires the involvement of independent, UK-regulated prescribers and pharmacies at every step, which is why the UK version is built around private healthcare partners rather than a single Lilly-run pipeline ^[1].

What happens next

Lilly has indicated Foundayo (orforglipron) could be added to LillyDirect UK later in 2026 if the MHRA approves the oral GLP-1 drug for private prescription before year's end ^[1]. No timeline has been given for whether additional Lilly medicines or additional dispensing partners will be added to the UK platform ^[1].